Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Associate Professor Will Herrington

Associate Professor Will Herrington

Will Herrington


MRC-Kidney Research UK Professor David Kerr Clinician Scientist

  • Associate Professor, Renal Studies Group, MRC Population Health Research Unit, Clinical Trial Service Unit and Epidemiological Studies Unit, Univ. of Oxford
  • Honorary Consultant Nephrologist, Oxford Kidney Unit


Will Herrington is a Medical Research Council-Kidney Research UK Professor David Kerr clinician scientist based at the Nuffield Department of Population Health, University of Oxford and a practising Honorary Consultant Nephrologist at Oxford Kidney Unit. He joined the Renal Studies Group as a Clinical Research Fellow and trained on landmark renal trials (SHARP, 3C and UKHARP3). In 2013, he was awarded an MD from the University of Cambridge for a thesis entitled ‘The effects of lowering LDL cholesterol on stroke in chronic kidney disease’.

He co-leads the EMPA-KIDNEY trial, which is testing the effects of empagliflozin 10mg versus placebo on cardiorenal outcomes in 6609 people with chronic kidney disease with and without diabetes. He also co-chairs the UK Kidney Association guideline working group responsible for recommendations on the use of SGLT-2 inhibitors in adults with kidney disease, and has chaired the UK Renal Trials Network since 2020.

He also aims to better understand the key determinants of kidney disease development and progression using observations from large blood-based prospective cohorts across a wide range of different populations. He has a particular focus on adiposity and its related risk factors, and how these may interlink to also cause cardiovascular disease.

Key publications

Recent publications

More publications